Gene-drug Pairings for Antidepressants & Antipsychotics: Level of Evidence & Clinical Application
As part of the update on Genomind PGx test, there is a recent Expert Review on “Gene-drug Pairings for Antidepressants & Antipsychotics: Level of Evidence & Clinical Application”.
The current consensus among experts in pharmacogenetics is that CYP2D6 and CYP2C19 genotype information should be used to inform treatment recommendations for a large number of antidepressants and antipsychotics. This strategy is increasingly applied in routine clinical care, particularly for patients showing poor responses to previous treatments.
Click the file below to read the full review.
